Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 82.48%: Read This Before Placing a Bet

Core Viewpoint - Ocular Therapeutix (OCUL) shares have increased by 6.7% recently, with a mean price target of $22.08 suggesting a potential upside of 82.5% from the current price of $12.1 [1] Price Targets - The average of 12 short-term price targets ranges from a low of $18.00 to a high of $31.00, with a standard deviation of $4.23, indicating variability among analysts [2] - The lowest estimate suggests a 48.8% increase, while the highest points to a 156.2% upside [2] Analyst Consensus - There is strong agreement among analysts regarding OCUL's ability to report better earnings than previously predicted, which supports the potential for stock upside [4] - The Zacks Consensus Estimate for the current year has risen by 2.5% over the past month, with five estimates increasing and no negative revisions [12] Zacks Rank - OCUL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside [13] Earnings Estimate Revisions - Increasing optimism among analysts about OCUL's earnings prospects is reflected in the upward revisions of EPS estimates, which have a strong correlation with near-term stock price movements [11]